

”Aiming for the clinics”

– Strengthened interactions in translational medicine

Date: May 8, 2024

Venue: Lecture Hall IX, University main building, Biskopsgatan 3, Uppsala

AGENDA

9.00 Welcome!

Kristian Sandberg, SciLifeLab Drug and Development platform (DDD), Platform Co-Director and *Maria Ericsson Svensson*, Director of Uppsala Clinical Research Center (UCR)

9.10 Introduction to SciLifeLab and the Drug and Development platform (DDD) national infrastructure and competences

Kristian Sandberg

9.35 Introduction to Uppsala Clinical Research Center (UCR)

Maria Eriksson Svensson

10.00 – 10.30 Coffee Break

INSPIRATIONAL CASE STUDIES FOR ATMP, SMALL MOLECULES AND THERAPEUTIC OLIGONUCLEOTIDES

10.30 From invention to clinical development using immunostimulatory gene therapy for cancer

Angelica Loskog, Uppsala University

11.00 Personalized Tumor-Trained Lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer

Samuel Svensson, NEOGAP

11.30 Histamine dihydrochloride for relapse prevention in acute myeloid leukemia: from bench to bedside

Kristoffer Hellstrand, Gothenburg University

12.00 – 13.00 LUNCH

13.00 Oligonucleotide therapy for neurodegenerative diseases – challenges and opportunities

Sarah Tabrizi, Kings College, London, UK

14.00– 14.20 Coffee Break

CONSIDERATIONS WHEN AIMING FOR THE CLINICS

14.20 Statistical aspects in clinical drug development

Olof Petter Östlund, UCR

14.55 Innovation support from the Medical Products Agency (MPA)

Gunilla Andrew-Nielsen, Medical Products Agency, Sweden

15.30 – 16.30 Mingle and ”Meet the Experts” – poster session with confirmed participation from RISE (Research Institutes of Sweden), The Swedish Medical Products Agency (Läkemedelsverket), Testa Center, SciLifeLab Drug Discovery & Development, Uppsala University Innovation, The Swedish Drug Delivery Center (SweDeliver), CCRM Nordic, Uppsala Clinical Research Center (UCR), ATMP-Center Uppsala, UU samverkan, Uppsala Preclinical Cancer Treatment Center, NorthX Biologics, Precisionsmedicinskt centrum Uppsala (PMCU), NorthX Biologics and The Swedish Medical Products Agency (Läkemedelsverket).